Trending Articles

article thumbnail

State-of-the-art covalent virtual screening with AlphaFold3

Covalent Modifiers

Yoav Shamir, Nir London bioRxiv 2025.03.19.642201 doi: [link] Recent years have seen an explosion in the prominence of covalent inhibitors as research and therapeutic tools. However, a lag in application of computational methods for covalent docking slows progress in this field. AI models such as AlphaFold3 have shown accuracy in ligand pose prediction but were never assessed for virtual screening.

article thumbnail

Scientists apply optical pooled CRISPR screening to identify potential new Ebola drug targets

Broad Institute

Scientists apply optical pooled CRISPR screening to identify potential new Ebola drug targets By Leah Eisenstadt July 24, 2025 Breadcrumb Home Scientists apply optical pooled CRISPR screening to identify potential new Ebola drug targets Combining powerful imaging, perturbational screening, and machine learning, researchers uncover new human host factors that alter Ebola’s ability to infect.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Millipedes make ants dizzy — and might soon treat human pain

Science Daily: Pharmacology News

Millipedes, often dismissed as creepy crawlies, may hold the secret to future painkillers and neurological drugs. Researchers at Virginia Tech discovered unique alkaloid compounds in the defensive secretions of a native millipede species. These complex molecules, which cause disorientation in ants, interact with human neuroreceptors linked to pain and cognition.

article thumbnail

Designing antibodies to think before they bind

Drug Target Review

Antibody therapies have transformed cancer treatment, yet their limits are becoming increasingly clear – particularly when tumours evolve, evade immune detection or develop resistance to existing drugs. For Dr Jhong-Jhe ‘JJ’ You, Vice President of Antibody Discovery at AP Biosciences, these challenges are not setbacks. They are starting points. With a background in neurobiology, immuno-oncology and bispecific engineering, JJ now leads the development of antibody candidates designed to go further

article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

Synthesis and Bioactivity Evaluation of Novel Sulfonamide‐1,2,3‐Triazole Hybrids: In Vitro and In Silico Studies

Chemical Biology and Drug Design

Novel 1,2,3-triazole derivatives incorporating a 4-iodosulfonamide moiety were synthesized. Their antioxidant properties were evaluated using DPPH, ABTS, and CUPRAC methods. The inhibitory activity of the compounds against cholinesterases (AChE and BuChE) was investigated. An investigation of their anticancer properties against Caco-2 and PC3 cancer cell lines was also conducted.

article thumbnail

Why Mallory Freeberg is creating a perturbation catalogue

The Open Targets Blog

How can you work out the function of a particular gene or protein across different cell types and functions? If you perturb it—modify it and observe the consequences—you can start to unravel what its biological role might be, and determine whether the effects are unique to one cell type or whether they propagate across different cell contexts.

More Trending

article thumbnail

The plant virus that trains your immune system to kill cancer

Science Daily: Pharmacology News

A virus from humble black-eyed peas is showing extraordinary promise in the fight against cancer. Unlike other plant viruses, the cowpea mosaic virus (CPMV) can awaken the human immune system and transform it into a cancer-fighting powerhouse, without infecting human cells. By comparing it to a similar, but ineffective, virus, researchers uncovered that CPMV uniquely triggers potent interferons and immune responses, making it a low-cost, plant-grown immunotherapy on the fast track toward clinica

article thumbnail

Fixing failed drugs: AI solutions for toxicity in drug discovery – part 3

Drug Target Review

When discussing how newer AI technologies like large language models (LLMs) could contribute to toxicity prediction, Hosseini-Gerami identified two key applications: 1. Improved scientist–data interaction: “Once we have all these datasets, have run these algorithms and have some outcomes and outputs, how can a scientist really engage with that information and use it to make a decision on what to do next?

article thumbnail

2‐Hydroxy‐3‐Methylanthraquinone Suppresses Hepatocellular Carcinoma Progression by Blocking Annexin A5‐Mediated Phosphatidylinositol 3‐Kinase/Protein Kinase B Signaling

Chemical Biology and Drug Design

Liver cancer is a form of aggressive tumor, with HCC accounting for most of its occurrences. Traditional Chinese herbal medicines are well-known for their low risks of adverse events and anticancer effects. HMA, the main active ingredient of Hedyotis diffusa Willd , has been shown to suppress the growth of several malignancies. Therefore, this study examined the effects of HMA in HCC.

article thumbnail

FDA Upgrades Recall on 160,000+ Bottles of Thyroid Medication

Drugs.com

THURSDAY, July 24, 2025 — The U.S. Food and Drug Administration (FDA) has upgraded a recall of a commonly prescribed thyroid medication due to what it described as "subpotent" active ingredients. The recall of more than 160,000 bottles of.

FDA
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Orelabrutinib, an irreversible inhibitor of Bruton’s tyrosine kinase, for the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, phase Ib/IIa study

Covalent Modifiers

Xue Li, Ru Li, Xiaoxia Zhu et al. Research Square Preprint, 23 July 2025, [link] Orelabrutinib is a highly selective, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). It has shown promising results in animal models, indicating potential for treating systemic lupus erythematosus (SLE). A multicentre, double-blind, randomised, placebo-controlled, phase Ib/IIa trial (NCT04305197) was conducted.

article thumbnail

This sugar substitute does more than sweeten — it kills cancer cells

Science Daily: Pharmacology News

Fermenting stevia with a banana leaf-derived probiotic turns it into a powerful cancer-fighting agent that kills pancreatic cancer cells while sparing healthy ones. The secret lies in a metabolite called CAME, produced through microbial transformation.

article thumbnail

Sygnature Discovery Completes Major Enhancement of High-Throughput Chemistry Facilities Following £1 Million Investment

Sygnature Discovery

Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), today announces the completion of a major enhancement to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure following a £1 million investment. In today’s demanding drug discovery landscape, accelerating time to value inflection remains a top industry priority.

article thumbnail

Vamorolone

New Drug Approvals

Vamorolone CAS 13209-41-1 Molecular Weight 356.46 Formula C 22 H 28 O 4 Agamree 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione VBP-15 free alcohol (8 S ,10 S ,13 S ,14 S ,16 R ,17 R )-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6 H -cyclopenta[a]phenanthren-3-one (16alpha)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta

FDA
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Insulin Nasal Spray Reaches Alzheimer's Targets, Brain Scans Show

Drugs.com

THURSDAY, July 24, 2025 — Insulin delivered by nasal spray might be a potential treatment for Alzheimer’s disease, a new study says. An insulin nasal spray effectively reached key memory regions in the brains of a small group of older.

article thumbnail

CDD Vault Update (July #2 2025) Search Inventory by Molecule & Batch Fields, Protocol Plate Locations, Stoichiometry Table Debiting, Synonym Links in ELN, Chemical Properties in Structure Editor

Collaborative Drug

CDD Vault Update (July #2 2025) Search Inventory by Molecule & Batch Fields, Protocol Plate Locations, Stoichiometry Table Debiting, Synonym Links in ELN, Chemical Properties in Structure Editor

article thumbnail

Ivermectin: The mosquito-killing pill that dropped malaria by 26%

Science Daily: Pharmacology News

A groundbreaking study has revealed that the mass administration of ivermectin—a drug once known for treating river blindness and scabies—can significantly reduce malaria transmission when used in conjunction with bed nets.

article thumbnail

Cracking the Code: Using Drug Patents to Reveal Competitor Formulation Strategies

Drug Patent Watch

Uncovering the Secret Formulas: How Drug Patents Reveal the Competition's Playbook As the pharmaceutical industry continues to evolve, companies are under increasing pressure to innovate and stay ahead of the curve. But what if the key to unlocking your competitors' strategies lies in plain sight – hidden in the complex web of drug patents? A new analysis from Drug Patent Watch reveals the surprising ways in which competitors are using patent data to inform their formulation strategies.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

ACTO LAUNCHES CXZONE: THE FIRST AI-SIMULATED ROLEPLAY SOLUTION BUILT EXCLUSIVELY FOR LIFE SCIENCES FIELD PROFESSIONALS AND INTEGRATED WITH VEEVA PROMOMATS AND MEDCOMMS

ACTO

A Specialized Practice Environment to Sharpen Clinical Fluency, Master Product Messaging, and Drive Continuous Improvement Through a Gamified Experience BTORONTO and NEW YORK– July 24, 2025 — ACTO , a leader in AI-first commercial learning, enablement, and customer engagement solutions for life sciences and a Veeva Product Partner and member of the Veeva AI Partner Program, today announced the launch of CxZone , the first and only AI-simulated roleplay solution exclusively designed for pharmaceu

article thumbnail

FDA Approves First Cream for Treating Chronic Hand Eczema, Anzupgo

Drugs.com

THURSDAY, July 24, 2025 — The U.S. Food and Drug Administration (FDA) has signed off on the first-ever cream specifically approved for treating chronic hand eczema (CHE). CHE is common condition marked by redness, itching and cracking on the.

article thumbnail

Spalt‐Like Transcription Factor 4 Mediates Fatty Acid Oxidation to Foster 5‐Fluorouracil Resistance in Gastric Cancer Cells

Chemical Biology and Drug Design

Spalt-like transcription factor 4 (SALL4) mediates fatty acid oxidation (FAO) promotes 5-fluorouracil (5-FU) resistance in gastric cancer (GC) cells. ABSTRACT Platinum-based and pyrimidine drugs are first-line treatments for gastric cancer (GC), but their efficacy is often affected by drug resistance. High spalt-like transcription factor 4 (SALL4) expression is associated with poor prognosis, but its role in 5-fluorouracil (5-FU) resistance is not yet clear.

article thumbnail

Cancer cells go up in flames—thanks to this deep-sea sugar

Science Daily: Pharmacology News

Scientists have discovered a sugar compound from deep-sea bacteria that can destroy cancer cells in a dramatic way. This natural substance, produced by microbes living in the ocean, causes cancer cells to undergo a fiery form of cell death, essentially making them self-destruct. In lab tests and in mice with liver cancer, the compound not only stopped tumors from growing, but also activated the immune system to fight back.

article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

The Patent Playbook Your Lawyers Won’t Write: Patent strategy development framework for pharmaceutical companies

Drug Patent Watch

"Patent Strategy 2.0: Why Your Law Firm's Playbook May Be Holding You Back As the pharmaceutical industry continues to evolve at breakneck speed, one thing remains constant: the importance of a robust patent strategy. But are your lawyers playing by the same old rules? A new framework is emerging that's shaking up the status quo and giving companies a competitive edge.

article thumbnail

Drug Discovery Industry Roundup with Barry Bunin — July 22, 2025

Collaborative Drug

Drug Discovery Industry Roundup with Barry Bunin — July 22, 2025

article thumbnail

Lonza reports stronger-than-expected CDMO revenue in the first half of 2025

Pharma Manufacturing

The company saw positive momentum in mammalian, bioconjugates, and small molecules, offsetting lower sales from its cell and gene therapy and microbial businesses.

article thumbnail

Oyez, Oyez, Oyez! Effective August 1, DEA Will Have No Administrative Law Judges

FDA Law Blog: Biosimilars

By John A. Gilbert & Karla L. Palmer & Larry K. Houck & Andrew J. Hull — Last week, DEA registrants and applicants with pending actions before DEA’s Office of Administrative Law Judges (OALJ) received an order from Chief Administrative Law Judge John J. Mulrooney, II, staying the hearing proceedings in those cases. In those orders, Chief Judge Mulrooney announced that he was retiring from the bench effective August 1, 2025, and that, in the absence of any other DEA ALJs, all proceed

article thumbnail

A deadly virus no one talks about — and the HIV drugs that might stop it

Science Daily: Pharmacology News

HIV antivirals may be the key to stopping HTLV-1, a deadly virus with no cure. In a decade-long study, researchers successfully suppressed the virus in mice and discovered a way to kill infected cells, offering hope for the first preventative and curative treatments.

article thumbnail

Overcoming Formulation Challenges in Generic Drug Development

Drug Patent Watch

"Breaking the Patent Barrier: The Unseen Hurdles in Generic Drug Development As the pharmaceutical industry grapples with rising costs and accessibility concerns, generic drug development has emerged as a beacon of hope. However, behind the scenes, generic manufacturers are facing a daunting challenge: overcoming formulation hurdles that can make or break the success of a generic drug.

article thumbnail

Highlights From the International Society for the Advancement of Cytometry Conference 2025 by Martin Turcotte

Alta Sciences

Highlights From the International Society for the Advancement of Cytometry Conference 2025 by Martin Turcotte pmjackson Wed, 07/23/2025 - 17:38 CYTO 2025 , the 38th annual Congress of the International Society for the Advancement of Cytometry, is the premier, inclusive, and international conference on the many facets of cytometry science and engineering.

article thumbnail

Inside Oncology Drug Development: Overcoming Resistance with Science

Crown Bioscience

The Patient’s Journey: An Emotional and Scientific Challenge At the heart of drug resistance lies a deeply personal story - each slide of a patient’s tissue sample represents an individual’s journey of courage and hope in navigating a challenging chapter of their life. As Enrico shared in the podcast, understanding drug resistance is not only a scientific endeavor but also a commitment to improving lives.

article thumbnail

GenAI and real-world data in pharma: 4 questions to fuel effective insights

BioPharma Drive: Drug Pricing

Skip to main content Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.

article thumbnail

HP&M Welcomes Peter Dickos to the Firm

FDA Law Blog: Biosimilars

Hyman, Phelps & McNamara, P.C. (“HP&M”) is pleased to announce that Peter “Pete” Dickos has joined the firm as Counsel. Pete brings nearly a decade of high-level government experience to HP&M’s Enforcement and Litigation practice, with a particular focus on complex regulatory and litigation challenges involving the U.S. Food and Drug Administration (FDA).